Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
The remarkable speed of the company’s cystic fibrosis triplet approval will not distract attention from its price.
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.